Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory

 

 

 
Bayer Schering Pharma AG Halts FVIII Study
 

The Germany-based specialty pharmaceutical company Bayer Schering Pharma AG announced in January that it has discontinued a Phase II clinical trial (the LIPLONG study) for BAY79-4980, a long-acting recombinant factor VIII (rFVIII) therapy. The decision was made after an interim analysis and subsequent recommendation by an independent Data Safety and Monitoring Board (DSMB). DSMB concluded that the study would not achieve “the predetermined efficacy endpoint (non-inferiority).” The company added that no safety concerns were raised.

 

LIPLONG was a randomized, double-blind active comparator controlled study designed to demonstrate the non-inferiority of BAY79-4980 infused in hemophilia A patients weekly, compared to Kogenate® FS, another of Bayer’s rFVIII products, which is infused three times per week.

“While we are disappointed with the outcome of the analysis, we remain committed to developing our long-acting recombinant factor VIII compounds,” said Kemal Malik, MD, member of the Board of Management of Bayer Schering Pharma AG and Head of Global Development. “It is our goal to enable once weekly prophylaxis dosing as well as other factor therapies, such as BAY VII, a modified recombinant factor VII therapy for hemophilia A and B in patients with inhibitors.”

 

Bayer also reported that it will continue to analyze the LIPLONG data.

 

Source: Bayer HealthCare press release dated January 25, 2010